What are the treatment options for Sturge‑Weber syndrome?

Treatment of Sturge-Weber Syndrome

For Sturge-Weber syndrome, implement a multidisciplinary treatment approach centered on aggressive seizure control with antiseizure medications (ASMs), low-dose aspirin prophylaxis, presymptomatic treatment when brain involvement is identified, and consideration of early surgical intervention for drug-resistant epilepsy. 1, 2, 3

Neurological Management

Seizure Control - The Primary Priority

Aggressive seizure control is paramount as it directly impacts neurodevelopmental outcomes and quality of life 1, 3. The evidence strongly supports:

• Initiate ASMs immediately upon seizure onset - First seizures in SWS are frequently prolonged, with 46% requiring phenytoin administration for status epilepticus 4
• Consider presymptomatic ASM prophylaxis in infants with confirmed brain involvement on MRI, even before seizures develop 3, 5, 4
  • In one series, 50% of infants on prophylactic ASMs remained seizure-free at 2-10 years follow-up
  • No patients on prophylaxis experienced status epilepticus >30 minutes 4

Low-Dose Aspirin Therapy

Administer low-dose aspirin as preventive therapy to reduce stroke-like episodes and potentially decrease seizure frequency 1, 3, 5. While not universally utilized, current literature increasingly supports this approach for reducing the frequency and severity of both seizures and stroke-like events 1.

Surgical Intervention for Drug-Resistant Epilepsy

For patients with multilobar involvement and drug-resistant epilepsy, surgical treatment significantly improves outcomes 6:

• Surgical indications include: (1) AED-resistant seizures, (2) developmental delay, and (3) cortical atrophy 6
• Seizure-free rates: 85.7% with surgery vs. 58.6% with medical management alone 6
• Surgery improved both seizure control AND cognitive outcomes, even in patients with more severe baseline impairment 6
• For whole hemisphere involvement, hemispherectomy is optimal 6
• For 2-3 lobe involvement, limited resection of epileptogenic tissue should be considered 1, 6

Emerging and Adjunctive Therapies

Newer treatments showing promising early results include:

• Cannabidiol - supported by prospective drug trials 5
• mTOR inhibitors (Sirolimus) - prospective trials demonstrate usefulness 1, 5
• Vitamin D supplementation - retrospective studies suggest benefit 5

Dermatological Management

Treat facial port-wine birthmark with selective photothermolysis using pulsed dye laser 1, 2. This addresses the characteristic facial capillary malformation.

Ophthalmological Management

Diagnostic Approach

Use enhanced depth imaging spectral-domain optical coherence tomography (EDI-SDOCT) as the primary imaging modality for detecting diffuse choroidal hemangioma (DCH) 7:

• EDI-SDOCT demonstrates 100% sensitivity and 100% accuracy vs. 35.7% sensitivity for fundus photography 7
• Enables early diagnosis even in pediatric patients with limited cooperation 7

Glaucoma Management

Implement medical and/or surgical management as indicated 1, 2. Regular ophthalmologic monitoring is essential given the high risk of glaucoma and ocular vascular anomalies.

Critical Diagnostic Considerations

Obtain MRI with AND without gadolinium contrast after 1 year of age 3, 4:

• Before 1 year, neuroimaging has low sensitivity and may underestimate involvement 3
• 31% of infants experienced delayed SWS diagnosis due to lack of gadolinium enhancement on initial MRI 4
• Pathognomonic findings include unilateral leptomeningeal angiomatosis, typically ipsilateral to facial birthmark 1

Common Pitfalls to Avoid

1. Delaying diagnosis: 55% of first seizures occurred before diagnostic MRI or tertiary referral 4
2. Inadequate initial imaging: Always use gadolinium contrast; non-contrast MRI misses critical leptomeningeal enhancement 4
3. Waiting for seizures to start treatment: Presymptomatic prophylaxis shows clear benefit in delaying or preventing seizure onset 3, 5, 4
4. Underestimating surgical candidacy: Proper patient selection for surgery dramatically improves both seizure and cognitive outcomes 6
5. Using fundus photography alone for choroidal hemangioma screening: This misses 64.3% of cases that EDI-SDOCT would detect 7

Timing of Interventions

• Immediate: Low-dose aspirin upon brain involvement confirmation
• Presymptomatic: ASM prophylaxis when MRI shows leptomeningeal involvement, before seizures
• At seizure onset: Aggressive ASM therapy; be prepared for status epilepticus
• Early consideration: Surgical evaluation if seizures prove resistant to 2-3 ASMs
• Ongoing: Regular ophthalmologic monitoring with EDI-SDOCT, neurocognitive assessment